IDEXX Laboratories Inc (IDXX)

Currency in USD
704.23
+6.21(+0.89%)
Closed·
703.70-0.53(-0.08%)
·
IDXX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
702.53711.23
52 wk Range
500.61769.98
Key Statistics
Prev. Close
704.23
Open
710.24
Day's Range
702.53-711.23
52 wk Range
500.61-769.98
Volume
392.45K
Average Volume (3m)
567.84K
1-Year Change
2.0727%
Book Value / Share
23.73
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
IDXX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
717.17
Upside
+1.84%
Members' Sentiments
Bearish
Bullish
ProTips
Management has been aggressively buying back shares

IDEXX Laboratories Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy

Analyst Ratings

9 Buy
4 Hold
1 Sell
Ratings:
14 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 717.17
(+1.84% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Jefferies
Buy770.00+9.34%705.00MaintainNov 03, 2026
Morgan Stanley
Buy810.00+15.02%805.00MaintainNov 03, 2026
UBS
Hold700.00-0.60%627.00MaintainNov 03, 2026
Leerink
Buy725.00+2.95%715.00MaintainNov 02, 2026
UBS
Hold627.00-10.97%670.00MaintainOct 27, 2026

IDEXX Laboratories Inc SWOT Analysis


Market Leadership
Explore IDEXX's dominance in veterinary diagnostics, balancing declining visits with increased utilization and innovative product launches
Financial Resilience
Despite market headwinds, IDEXX maintains robust profitability with a 60.7% gross margin and 7.2% revenue growth, showcasing its financial strength
Growth Projections
Analysts forecast sustainable double-digit top-line growth for IDEXX, with price targets ranging from $481 to $630, reflecting optimistic long-term outlook
Strategic Innovation
Delve into IDEXX's product development strategy, including the inVue Dx Analyzer and IDXX Cancer Dx, driving competitive advantage in a evolving market
Read full SWOT analysis

IDEXX Laboratories Inc Earnings Call Summary for Q3/2026

  • IDEXX Q3 2026 EPS of $3.96 beat estimates by $0.24; revenue of $1.21B topped forecasts; shares surged 17.2% to $646 in premarket trading.
  • Organic revenue grew 10% driven by companion animal diagnostics and reference labs; gross margin expanded 110 bps to 62.9%, operating margin up to 33.1%.
  • Company raised full-year 2026 guidance: revenue now $4.74B-$4.77B, EPS $14.96-$15.16, up from prior midpoint of $14.71; organic growth 9.3%-10% expected.
  • Management emphasized growth independent of clinic visits through diagnostic utilization gains, new products including inVue Dx and Cancer Dx multi-panel tests.
  • Key risks include soft U.S. vet visit trends down 1.8%, macro pressures on consumer spending, and execution challenges on CoVet acquisition integration.
Last Updated: 2026-11-02, 09:40 a/m
Read Full Transcript

Earnings

Latest Release
Nov 02, 2026
EPS / Forecast
3.96 / 3.72
Revenue / Forecast
1.21B / 1.19B
EPS Revisions
Last 90 days

IDXX Income Statement

Compare IDXX to Peers and Sector

Metrics to compare
IDXX
Peers
Sector
Relationship
P/E Ratio
46.9x26.7x−0.2x
PEG Ratio
2.651.120.00
Price/Book
29.7x2.7x2.6x
Price / LTM Sales
11.9x2.7x2.8x
Upside (Analyst Target)
1.8%0.0%65.0%
Fair Value Upside
Unlock7.8%9.5%Unlock

IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits. It also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments; UV Viewer Plus, a UV light cabinet which aids in the visual interpretation of fluorescent-based water tests; and veterinary software and services for independent veterinary clinics and corporate groups. In addition, the company offers diagnostic tests, services, and related instrumentation to manage the health status of livestock and poultry; human medical diagnostic products and services; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station. It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
41.79M53.04%29.43B
Other Institutional Investors
34.09M43.26%24.00B
Public Companies & Retail Investors
2.91M3.70%2.05B
Total
78.79M100.00%55.48B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
BlackRock, Inc.10.37%8,170,1785,753,684
Vanguard Capital Management, LLC7.11%5,603,8763,946,418

People Also Watch

283.03
GRMN
-1.10%
52.05
CSX
-0.67%
226.24
CTAS
-0.56%
287.52
ITW
+0.27%

FAQ

What Is the IDEXX Labs (IDXX) Stock Price Today?

The IDEXX Labs stock price today is 704.23 USD.

What Stock Exchange Does IDEXX Labs Trade On?

IDEXX Labs is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for IDEXX Labs?

The stock symbol for IDEXX Labs is "IDXX."

What Is the IDEXX Labs Market Cap?

As of today, IDEXX Labs market cap is 55.48B USD.

What Is IDEXX Labs's Earnings Per Share (TTM)?

The IDEXX Labs EPS (TTM) is 14.90.

When Is the Next IDEXX Labs Earnings Date?

IDEXX Labs will release its next earnings report on Feb 08, 2027.

From a Technical Analysis Perspective, Is IDXX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has IDEXX Labs Stock Split?

IDEXX Labs has split 4 times.

How Many Employees Does IDEXX Labs Have?

IDEXX Labs has 11000 employees.

What is the current trading status of IDEXX Labs (IDXX)?

As of Nov 16, 2026, IDEXX Labs (IDXX) is trading at a price of 704.23 USD, with a previous close of 704.23 USD. The stock has fluctuated within a day range of 702.53 USD to 711.23 USD, while its 52-week range spans from 500.61 USD to 769.98 USD.

What Is IDEXX Labs (IDXX) Price Target According to Analysts?

The average 12-month price target for IDEXX Labs is 717.17 USD, with a high estimate of 810 USD and a low estimate of 470 USD. 9 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +1.84% Upside potential.

What Is the IDXX Premarket Price?

IDXX's last pre-market stock price is 706.50 USD. The pre-market share volume is 1,290.00, and the stock has decreased by 8.48, or 1.21%.

What Is the IDXX After Hours Price?

IDXX's last after hours stock price is 703.70 USD, the stock has decreased by -0.53, or -0.08%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.